-The Indian Express The rights-based approach departs from the ‘assurance-based approach’ of the new National Health Policy, which essentially perpetuates the status quo, explains The Indian Express. Since the time the Mental Health Bill was introduced in Rajya Sabha in 2013, decriminalisation of suicide has been its calling card. However, the legislation travels beyond just that colonial era relic, assuming a rights-based approach to mental healthcare, and creating circumstances for removal of...

-The Hindu In the last three years, important entitlements for children have been undermined by the Centre The recent notification of the Ministry of Human Resource Development, making Aadhaar compulsory for midday meals in government schools, has attracted the criticism it deserves. This notification serves no clear purpose other than to force children to get enrolled under Aadhaar. The government, unfortunately, managed to create the impression that the notification had been retracted,...

-The Telegraph New Delhi: The Indian government is mulling monetary incentives to private doctors who provide correct treatment to patients with tuberculosis and financial and nutritional support to patients under new strategies to eliminate TB as a public health problem by 2025. The Union health ministry's "national strategic plan for tuberculosis elimination 2017-2025" also seeks to enhance investments in diagnostic tools and treatment to help cut the country's new TB cases from...

-Down to Earth Long-term exposure to organophosphate insecticides puts the farming community at a higher risk of developing diabetes, shows a study IN 2011, a 15-year-old girl from Madurai was admitted to hospital for diabetes ketoacidosis. It is a life-threatening condition that develops when cells in the body are unable to get the sugar (glucose) they need due to the lack of insulin. Krishnan Swaminathan, an endocrinologist and president of the...

-The Hindu In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food & Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer. Roche effectively embroiled India’s...